Comparison of the Clinical Features of Hepatitis A in People Living with HIV between Pandemics in 1999-2000 and 2017-2018 in the Metropolitan Area of Japan.
Adult
Anti-Retroviral Agents
/ adverse effects
CD4 Lymphocyte Count
CD8-Positive T-Lymphocytes
Cities
/ epidemiology
Coinfection
/ virology
Genome, Viral
HIV Infections
/ epidemiology
Hepatitis A
/ epidemiology
Hepatitis A Antibodies
/ blood
Hepatitis A virus
/ genetics
Homosexuality, Male
Humans
Japan
/ epidemiology
Liver
/ drug effects
Male
Middle Aged
Sexual and Gender Minorities
CD4/CD8 ratio
HIV
hepatitis A
hepatocellular damage
Journal
Japanese journal of infectious diseases
ISSN: 1884-2836
Titre abrégé: Jpn J Infect Dis
Pays: Japan
ID NLM: 100893704
Informations de publication
Date de publication:
24 Mar 2020
24 Mar 2020
Historique:
pubmed:
2
11
2019
medline:
21
10
2020
entrez:
1
11
2019
Statut:
ppublish
Résumé
Since 2017, hepatitis A virus (HAV) infection has been an epidemic among men who have sex with men (MSM) in Japan. We have come across 11 MSM patients with hepatitis A who were also infected with HIV. In 1999-2000, we came across 5 HIV-infected patients with hepatitis A. Since the conditions of current HIV-infected patients have changed owing to the recent progress in anti-HIV therapies, we compared clinical features of hepatitis A between patients in 2017-2018 and those in 1999-2000. By comparing the background characteristics of the patients, we found that the CD4/CD8 ratio was significantly higher in the 2017-2018 group. After the onset of hepatitis, peak levels of hepatic transaminases were found to be higher in the 2017-2018 group, suggesting severe hepatocellular damage. In contrast, neither the peak level of total bilirubin nor the nadir of prothrombin time was significantly different among the 2 groups. We also analyzed the HAV genome derived from some of the recently infected patients, and found that the HAV strains were almost the same among these patients; slight differences were observed from the previously identified strain. Thus, we concluded that the recovery of immunity by recent anti-HIV therapies may result in more severe hepatocellular damages and differences in clinical features.
Identifiants
pubmed: 31666497
doi: 10.7883/yoken.JJID.2019.275
doi:
Substances chimiques
Anti-Retroviral Agents
0
Hepatitis A Antibodies
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM